BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 1650166)

  • 21. Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice.
    Sarisky RT; Bartus HR; Dennis SA; Quail MR; Nguyen TT; Wittrock RJ; Halsey WS; Bacon TH; Leary JJ; Sutton D
    BMC Infect Dis; 2001; 1():24. PubMed ID: 11749671
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency.
    Schinazi RF; del Bene V; Scott RT; Dudley-Thorpe JB
    J Antimicrob Chemother; 1986 Oct; 18 Suppl B():127-34. PubMed ID: 3025153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of 2,2'-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice.
    Liu WG; Chen ZJ; Song JZ; Ma ZX
    Antimicrob Agents Chemother; 1986 Feb; 29(2):278-80. PubMed ID: 2424367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of acyclovir, oxetanocin-G, and carbocyclic oxetanocin-G in combinations on the replications of herpes simplex virus type 1 and type 2 in Vero cells.
    Saijo M; Suzutani T; Yoshida I
    Tohoku J Exp Med; 1992 May; 167(1):57-68. PubMed ID: 1333651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Herpes simplex virus type 1 ribonucleotide reductase: selective and synergistic inactivation by A1110U and its iron complex.
    Porter DJ; Harrington JA; Spector T
    Biochem Pharmacol; 1990 Feb; 39(4):639-46. PubMed ID: 2154988
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.
    Spector T; Averett DR; Nelson DJ; Lambe CU; Morrison RW; St Clair MH; Furman PA
    Proc Natl Acad Sci U S A; 1985 Jun; 82(12):4254-7. PubMed ID: 2987969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey.
    Nugier F; Colin JN; Aymard M; Langlois M
    J Med Virol; 1992 Jan; 36(1):1-12. PubMed ID: 1315366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of the treatment protocol upon the in vivo efficacy of cidofovir (HPMPC) and of acyclovir (ACV) formulations in topical treatment of cutaneous HSV-1 infection in hairless mice.
    Afouna MI; Mehta SC; Ghanem AH; Higuchi WI; Kern ER; DeClercq E; El-Shattawy HH
    J Pharm Sci; 1999 May; 88(5):530-4. PubMed ID: 10229644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acyclovir treatment of experimental genital herpes simplex virus infections. I. Topical therapy of type 2 and type 1 infections of mice.
    Kern ER; Richards JT; Overall JC; Glasgow LA
    Antiviral Res; 1983 Nov; 3(4):253-67. PubMed ID: 6320718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of a combination of ponicidin and acyclovir/ganciclovir to the antitumor efficacy of the herpes simplex virus thymidine kinase gene therapy system.
    Hayashi K; Hayashi T; Sun HD; Takeda Y
    Hum Gene Ther; 2002 Feb; 13(3):415-23. PubMed ID: 11860708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient.
    Lebel A; Boivin G
    J Clin Virol; 2006 Sep; 37(1):34-7. PubMed ID: 16781887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical formulations containing Trichilia catigua extract as therapeutic options for a genital and an acyclovir-resistant strain of herpes recurrent infection.
    Ribelato EV; Wouk J; Celestino GG; Rodrigues BCD; Darido MLG; Barboza MGL; Botura TJ; de Oliveira MC; de Andrade FG; Lonni AASG; de Mello JCP; da Rocha SPD; Faccin-Galhardi LC
    Braz J Microbiol; 2023 Sep; 54(3):1501-1511. PubMed ID: 37338788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nucleotide sequence of thymidine kinase gene of sequential acyclovir-resistant herpes simplex virus type 1 isolates recovered from a child with Wiskott-Aldrich syndrome: evidence for reactivation of acyclovir-resistant herpes simplex virus.
    Saijo M; Suzutani T; Itoh K; Hirano Y; Murono K; Nagamine M; Mizuta K; Niikura M; Morikawa S
    J Med Virol; 1999 Aug; 58(4):387-93. PubMed ID: 10421406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptide Inhibitor of Complement C1, RLS-0071, Reduces Zosteriform Spread of Herpes Simplex Virus Type 1 Skin Infection and Promotes Survival in Infected Mice.
    Bhutta MS; Sausen DG; Reed KM; Gallo ES; Hair PS; Lassiter BP; Krishna NK; Cunnion KM; Borenstein R
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Azone upon the in vivo antiviral efficacy of cidofovir or acyclovir topical formulations in treatment/prevention of cutaneous HSV-1 infections and its correlation with skin target site free drug concentration in hairless mice.
    Afouna MI; Fincher TK; Zaghloul AA; Reddy IK
    Int J Pharm; 2003 Mar; 253(1-2):159-68. PubMed ID: 12593946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management.
    Piret J; Boivin G
    Curr Opin Infect Dis; 2016 Dec; 29(6):654-662. PubMed ID: 27306564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture.
    Lawetz C; Liuzzi M
    Antiviral Res; 1998 Jul; 39(1):35-46. PubMed ID: 9754948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo antiherpetic effects of (1R,2R)-1-(5'-methylful-3'-yl)propane-1,2,3-triol.
    Sasaki K; Hayashi K; Matsuya Y; Sugimoto K; Lee JB; Kurosaki F; Hayashi T
    J Nat Med; 2016 Apr; 70(2):217-24. PubMed ID: 26763002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Transpl Infect Dis; 2013 Oct; 15(5):457-65. PubMed ID: 23895431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterisation of acyclovir-resistant and -sensitive clinical herpes simplex virus isolates from an immunocompromised patient.
    Christophers J; Sutton RN
    J Antimicrob Chemother; 1987 Sep; 20(3):389-98. PubMed ID: 2824424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.